Healthcare >> CEO Interviews >> December 2, 1999
LEONARD S. SCHLEIFER, M.D., Ph.D. is President and Chief Executive
Officer of Regeneron Pharmaceuticals, Inc. A native of Queens, New York,
Dr. Schleifer graduated Phi Beta Kappa and summa cum laude from Cornell
University, after which he was awarded his M.D. and Ph.D. in
Pharmacology from the University of Virginia. Dr. Schleifer continued
his medical training as an intern and resident in the Department of
Neurology at the New York Hospital-Cornell Medical Center in New York
City, where he currently holds the appointment of Clinical Professor of
Neurology and Neuroscience. Dr. Schleifer was certified in Neurology by
the American Board of Psychiatry and Neurology. Dr. Schleifer co-
authored articles published in the current edition of Good and Gilman's
The Pharmacological Basis of Therapeutics, about therapy of epilepsies
and drugs for Parkinson's disease, spasticity, and acute muscle spasms.
Dr. Schleifer is a member of the American Academy of Neurology, the
Society for Neuroscience, and the Royal Society of Medicine. In 1988,
Dr. Schleifer joined with Eric M. Shooter, Ph.D., a leading researcher
in the area of nerve growth factors and the founding Chairman of the
Department of Neurology at Stanford University's School of Medicine, and
Alfred G. Gilman, M.D., Ph.D., who received the 1994 Nobel Prize in
Medicine for Physiology, to found Regeneron. Dr. Schleifer is a member
of the Board of Directors of the Biotechnology Industry Organization. Profile
Dr. Schleifer: Since Regeneron opened its laboratories about 10 years
ago, we've been focused on using the tools of molecular
